Limits...
Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer.

Sun S, Liang X, Zhang X, Liu T, Shi Q, Song Y, Jiang Y, Wu H, Jiang Y, Lu X, Pang D - Br. J. Cancer (2015)

Bottom Line: High PGK1 expression was significantly associated with higher histologic grade (P=0.009) and positive status of ER (P=0.004), Her-2 (P=0.026) and P53 (P=0.012).High levels of PGK1 expression were associated with worse overall survival (OS, P=0.02).Multivariate analysis indicated that PGK1 (P=0.001) was an independent predictor in the patients treated with paclitaxel.

View Article: PubMed Central - PubMed

Affiliation: Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China.

ABSTRACT

Background: Phosphoglycerate kinase-1 (PGK1) has been recently documented in various malignancies; however, the molecular mechanisms of the variable PGK1 expression and its clinical significance in terms of survival status remain unclear.

Methods: Real-time quantitative PCR (real-time qPCR) and western blotting were used to verify PGK1 expression in 46 fresh breast cancer tissues and matched normal tissues. A tissue microarray (TMA) comprising 401 breast cancer tissues and 123 matched normal tissues was investigated by immunohistochemistry for PGK1 expression. Then, the correlation between PGK1 expression and the clinicopathologic features was analysed.

Results: PGK1 mRNA and protein expression were significantly increased in breast cancer tissues compared with that in normal breast tissues. High PGK1 expression was significantly associated with higher histologic grade (P=0.009) and positive status of ER (P=0.004), Her-2 (P=0.026) and P53 (P=0.012). High levels of PGK1 expression were associated with worse overall survival (OS, P=0.02). Furthermore, patients who underwent paclitaxel chemotherapy with high levels PGK1 expression had shorter OS than did those with low levels of PGK1 expression (P<0.001). Multivariate analysis indicated that PGK1 (P=0.001) was an independent predictor in the patients treated with paclitaxel.

Conclusions: PGK1 is a prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer.

Show MeSH

Related in: MedlinePlus

Kaplan–Meier analysis for survival based on PGK1 expression. (A) Survival curves showing the correlation of PGK1 with OS in breast cancer patients (P=0.02). (B) Overall survival based on PGK1 expression in patients treated with paclitaxel (P<0.001).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4402453&req=5

fig3: Kaplan–Meier analysis for survival based on PGK1 expression. (A) Survival curves showing the correlation of PGK1 with OS in breast cancer patients (P=0.02). (B) Overall survival based on PGK1 expression in patients treated with paclitaxel (P<0.001).

Mentions: Figure 3A shows that the OS was significantly higher in patients expressing elevated levels of PGK1 (P=0.02). The data indicated that high PGK1 expression was associated with worse OS; however, high PGK1 expression was not an independent prognostic factor.


Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer.

Sun S, Liang X, Zhang X, Liu T, Shi Q, Song Y, Jiang Y, Wu H, Jiang Y, Lu X, Pang D - Br. J. Cancer (2015)

Kaplan–Meier analysis for survival based on PGK1 expression. (A) Survival curves showing the correlation of PGK1 with OS in breast cancer patients (P=0.02). (B) Overall survival based on PGK1 expression in patients treated with paclitaxel (P<0.001).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4402453&req=5

fig3: Kaplan–Meier analysis for survival based on PGK1 expression. (A) Survival curves showing the correlation of PGK1 with OS in breast cancer patients (P=0.02). (B) Overall survival based on PGK1 expression in patients treated with paclitaxel (P<0.001).
Mentions: Figure 3A shows that the OS was significantly higher in patients expressing elevated levels of PGK1 (P=0.02). The data indicated that high PGK1 expression was associated with worse OS; however, high PGK1 expression was not an independent prognostic factor.

Bottom Line: High PGK1 expression was significantly associated with higher histologic grade (P=0.009) and positive status of ER (P=0.004), Her-2 (P=0.026) and P53 (P=0.012).High levels of PGK1 expression were associated with worse overall survival (OS, P=0.02).Multivariate analysis indicated that PGK1 (P=0.001) was an independent predictor in the patients treated with paclitaxel.

View Article: PubMed Central - PubMed

Affiliation: Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China.

ABSTRACT

Background: Phosphoglycerate kinase-1 (PGK1) has been recently documented in various malignancies; however, the molecular mechanisms of the variable PGK1 expression and its clinical significance in terms of survival status remain unclear.

Methods: Real-time quantitative PCR (real-time qPCR) and western blotting were used to verify PGK1 expression in 46 fresh breast cancer tissues and matched normal tissues. A tissue microarray (TMA) comprising 401 breast cancer tissues and 123 matched normal tissues was investigated by immunohistochemistry for PGK1 expression. Then, the correlation between PGK1 expression and the clinicopathologic features was analysed.

Results: PGK1 mRNA and protein expression were significantly increased in breast cancer tissues compared with that in normal breast tissues. High PGK1 expression was significantly associated with higher histologic grade (P=0.009) and positive status of ER (P=0.004), Her-2 (P=0.026) and P53 (P=0.012). High levels of PGK1 expression were associated with worse overall survival (OS, P=0.02). Furthermore, patients who underwent paclitaxel chemotherapy with high levels PGK1 expression had shorter OS than did those with low levels of PGK1 expression (P<0.001). Multivariate analysis indicated that PGK1 (P=0.001) was an independent predictor in the patients treated with paclitaxel.

Conclusions: PGK1 is a prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer.

Show MeSH
Related in: MedlinePlus